QualityStocksNewsBreaks Archives - Page 563 of 1499

ThursdayFeb 03, 2022 1:49 pm

QualityStocksNewsBreaks – InnerScope Hearing Technologies Inc. (INND) Announces Shareholder-Friendly Financing Arrangements

InnerScope Hearing Technologies (OTC: INND) is an emerging and disruptive leader in the direct-to-consumer hearing technology space. The company has announced its successful negotiation of the cancellation of a series of variable price convertible notes, with a total principal amount of $1.1 million held by GS Capital Partners LLC, resulting in a favorable restructuring of its financing agreements. “InnerScope is pleased to enter into these shareholder-friendly financing arrangements, which enhances our balance sheet and capital structure,” said Matthew Moore, president and CEO of InnerScope. “We appreciate the support from GS Capital in completing this transaction, as they continue to be…

ThursdayFeb 03, 2022 12:29 pm

QualityStocksNewsBreaks – Playgon Games Inc. (TSX.V: DEAL) (OTCQB: PLGNF) (FRA: 7CR) Celebrates Year of the Tiger with Proprietary Table Game

Playgon Games (TSX.V: DEAL) (OTCQB: PLGNF) (FRA: 7CR), a software-as-a-service (“SaaS”) company delivering mobile live dealer technology to online gaming operators globally, celebrates the Chinese New Year and Year of the Tiger with its proprietary table game Tiger Bonus Baccarat(R). “Baccarat is the highest-grossing casino game in the world, and we have seen tremendous success with this new Baccarat variant on our platform,” said Guido Ganschow, president of Playgon Interactive. “Tiger Bonus Baccarat(R) has quickly become a hit with our client's players and is showing no sign of slowing down. With our mobile first approach and the unique gameplay of…

ThursdayFeb 03, 2022 12:16 pm

QualityStocksNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Delic Labs to Present at Emerald Conference

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today announced that Dr. Markus Roggen, president and chief science officer for Delic Labs, will give a presentation on “Artificial Intelligence for Craft Cannabis Products” at the Emerald Conference. Dr. Roggen’s presentation is scheduled to begin at 12:45 p.m. PT on Monday, Feb. 28, 2022. “Focusing solely on extraction yields for cannabis extraction operations is an imprecise way to think about production,” said Dr. Roggen. “Quality of extract, cost of extraction and loss in post-processing should all be considered. Our laboratory…

ThursdayFeb 03, 2022 11:59 am

QualityStocksNewsBreaks – FuelPositive Corporation (TSX.V: NHHH) (OTCQB: NHHHF) News Highlighted in Recent NNA Syndicated Broadcast

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF), a growth stage company focused on licensing, partnership and acquisition opportunities building upon various technological achievements, is the center of attention in a recent NetworkNewsAudio (“NNA”) broadcast. The segment focuses on FuelPositive’s recent filing of its annual audited financial statements for the year ended Sept. 30, 2021, as well as the discussion and analysis provided by company management. NetworkNewsAudio broadcasts are distributed to thousands of syndication points and are designed to deliver additional visibility, recognition and brand awareness in the investment community. “FuelPositive is moving forward at full speed to commercialize our in situ, modular,…

ThursdayFeb 03, 2022 11:28 am

QualityStocksNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Strengthens Board with Appointment of Dr. Victoria Hale

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced the appointment of Dr. Victoria Hale to the company’s board of directors. A pharmaceutical scientist, executive and global health social entrepreneur, Dr. Hale currently serves as chair of the board of the Multidisciplinary Association for Psychedelic Studies (“MAPS”). A non-profit research and educational organization, MAPS works to raise awareness of psychedelics and help scientists design, fund and obtain regulatory approval of studies measuring the safety and effectiveness of psychedelics for therapeutic use. “We are thrilled to welcome…

WednesdayFeb 02, 2022 3:04 pm

QualityStocksNewsBreaks – Sugarmade Inc. (SGMD) Establishes Enviable Position in Legal Cannabis Market

Sugarmade (OTC: SGMD), an emerging leader in the licensed cannabis sector, is positioned in the growing legal cannabis market, which is expected to see an estimated 16.6% growth in the coming years. “At the beginning of 2021, Sugarmade CEO Jimmy Chan called 2020 a ‘landmark year’ for the company, telling shareholders that in 2021 SGMD would ‘continue to verticalize our model, creating a full farm-to-door structure that expects to produce high-quality branded cannabis products positioned in a vertical in-house supply chain. We expect that this will provide Sugarmade with optimal margins,’” a recent article reads. “The strategy for 2021 appears…

WednesdayFeb 02, 2022 2:56 pm

QualityStocksNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Blazing Trail in Defining Value of Rare Cannabinoids in Pharmaceutical Space

InMed Pharmaceuticals (NASDAQ: INM) is a trailblazer, a pioneer defining the value of rare cannabinoids in the pharmaceutical sector and just how integral they are in pushing the industry forward. The global cannabis market is experiencing tremendous growth, particularly considering there are over 100 known cannabinoids, including rare ones that are quickly taking over and will soon dominate the market. The potency of rare cannabinoids has given them powerful health benefits, hence their demand within the cosmetics, food and beverage, health and wellness, and pharmaceutical sectors. “InMed’s most advanced compound, INM-755, has already proven helpful in treating epidermolysis bullosa, a…

WednesdayFeb 02, 2022 2:44 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Laying Robust Foundation for Potentially Pivotal Global Trial

CNS Pharmaceuticals (NASDAQ: CNSP) recently received approval from swissethics, the umbrella organization of the cantonal Ethics Committees in Switzerland. The first from a European Ethics Committee, the approval marks a significant milestone for the company as it journeys toward its potentially pivotal study of Berubicin, an anthracycline, for the treatment of Glioblastoma Multiforme (“GBM”). The approval also partly fulfills CNS’s goal of seeing Berubicin approved for the potential treatment of GBM globally. GBM is one of the most aggressive, deadly and treatment-resistant cancers that form in the brain. “So far, the company has selected tens of clinical sites across the…

WednesdayFeb 02, 2022 2:35 pm

QualityStocksNewsBreaks – DigiMax Global Inc.’s (CSE: DIGI) (OTC: DBKSF) CryptoHawk Providing Bird’s-Eye View in Investing, Analysis in Crypto Price Trends

DigiMax Global’s (CSE: DIGI) (OTC: DBKSF) CryptoHawk is one of the world’s most powerful and complete crypto price prediction indicator tools available. CryptoHawk leverages deep learning algorithms to provide a bird’s-eye view of crypto investing, resulting in more efficient predictions. “As cryptocurrencies grow in popularity, new investors entering the space will soon find out that crypto price forecasting is extremely challenging due to the market’s price volatility and dynamism… CryptoHawk attempts to reduce some of these price forecasting challenges and is specifically designed to analyze crypto price trends and alert traders about key components that indicate the time may be right…

WednesdayFeb 02, 2022 2:14 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Significant Findings from Sildenafil Animal Study

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has reported positive findings in its recent animal study. The study was designed to evaluate LEXX’s proprietary DehydraTECH(TM) processing of the phosphodiesterase inhibitor ("PDE5 inhibitor") sildenafil for potential use in the management of erectile dysfunction. According to the company, the DehydraTECHsildenafil delivered 74% more drug at four minutes than the concentration-matched, generic control formulation with faster and higher overall delivery of sildenafil into the bloodstream evidenced over the course of the study. The most recognizable sildenafil product available currently is Viagra(R), but some users find it slow to act. Lexaria hopes…

Site Search

Company Search

Category: QualityStocksNewsBreaks